As the response to current antiarrhythmic drugs in an individual patient is highly variable and membrane-active drugs can be associated with significant toxicity, targeted inhibition of NOX2 may be a novel therapeutic approach for obese individuals at risk for AF and as adjunctive therapy for patients with obesity-mediated AF. This evidence concerns the gene CYBB and atrial fibrillation.